'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_89819

Personalised medicine 15-20 years away, say UK scientists

22 September 2005
By BioNews
Appeared in BioNews 327

The UK's Royal Society has published a report on the potential of pharmacogenetics - drug treatments tailored to a person's genetic make-up - following a year-long investigation into the subject. It concludes that although 'personalised medicines' have a promising future, it will be at least another 15-20 years before their use is widespread. The report, entitled 'Personalised medicines: hopes and realities', says this is down to the many gaps in our current understanding of how genetics relates to the causes of disease.

It is hoped that advances in pharmacogenetics will eventually lead to a drop in the number of adverse drug reactions, and an end to the 'trial and error' approach currently used to prescribe medicines. However, some scientists have expressed reservations about whether such technology will ever live up to the hype, what it might cost, and how it would impact on healthcare systems. There are also fears that since drug company profits depend on 'blockbuster' drugs taken by millions of people, it may prove too costly for them to develop a vast array of individually tailored medicines.

Sir David Weatherall, chair of the working group, said: 'Personalised medicines show promise but they have undoubtedly been over-hyped. With the human genome sequenced, some people are expecting personalised medicines within a few years, but the reality is still many years away. There are some examples around today, but the complex multiple causes of diseases mean it will be at least 15 to 20 years before a patient's genetic make-up is a major factor in determining which drugs they are prescribed'.

The report says that the development of personalised medicines is being held up by a lack of knowledge amongst healthcare professionals, and also a shortage of scientists trained to carry out pharmacogenetic research. 'With the NHS expected to spend £11billion on drugs in 2005-6, there is a need to invest in gathering data on how genes influence drug response in the patient population', said Weatherall, adding 'investment needs to come from both the public and private sectors'.

The report highlights the need for financial incentives level to encourage drug companies to work on developing personalised medicines with relatively small potential markets. Sir David also called for pharmaceutical companies to make 'better use' of genetic data collected during clinical trials, and to continue monitoring drugs once they are launched. In addition, further private sector input should come from companies that produce DNA tests, he said.

A report on the ethical and policy issues surrounding pharmacogenetics, published by the Nuffield Trust in 2003, identified reduced availability of some medicines as a potential area of concern. Meanwhile, a report on pharmacogenetics carried out by the Department of Health entitled 'My very own medicine: What must I know?' cautioned that 'media excitement about genetic applications may be exaggerating investment and research activity' in this area.

Personalised drugs 'decades away'
BBC News Online |  21 September 2005
Personalised medicines: hopes and realities
The Royal Society |  21 September 2005
Personalised medicines over-hyped, report says
Reuters |  21 September 2005
10 December 2018 - by Shaoni Bhattacharya 
The UK scientist Professor Sir David Weatherall, who was the first to show that a gene deletion could cause a human disease, has passed away...
20 June 2011 - by Ruth Pidsley 
US scientists have reported possibly the first example of using one person's genetic sequence to refine a diagnosis and provide personalised medical treatment. Whole-genome sequencing (WGS) helped pinpoint defects in the DNA of 14-year-old fraternal twins Noah and Alexis Beery causing their rare neurological condition, dopamine-responsive dystonia (DRD)...
18 October 2010 - by MacKenna Roberts 
The UK's Nuffield Council on Bioethics has reported that direct-to-consumer personal genetic profiling services used to predict people's genetic susceptibility for common diseases, such as Parkinson's and diabetes, are often inconclusive, misleading and can potentially cause unnecessary anxiety, complacency or distress when no treatment is available...
10 October 2005 - by BioNews 
Japanese companies have built a desk-top machine that allows doctors to check their patients' DNA before writing a prescription, the journal Nature reports. The device, which they say will be on sale for five million yen (£25,000) in a year's time, uses a single drop of blood and delivers results...
21 September 2004 - by BioNews 
The UK's Royal Society is launching a year-long investigation into the potential of pharmacogenetics: drug treatments tailored to a person's genetic make-up. The study, headed by geneticist Sir David Weatherall, will look at when and if 'personalised medicine' will become a reality. It will also assess whether healthcare providers in...
10 September 2004 - by BioNews 
A genetic test that helps predict how people will react to certain medicines has been approved for sale in the European Union, Swiss firm Roche Diagnostics has announced. The test, called the AmpliChip CYP450, detects variations in two genes that make key liver enzymes. Variations in the activity of these...
23 June 2004 - by BioNews 
Research into pharmacogenetics - the use of genetic tests to match medicines to a person's genetic make-up - is to receive £4 million of funding, Health Minister Lord Warner announced last week. The cash will go to six different research projects, which include studies on medicines used to prevent blood clots, epilepsy...
25 September 2003 - by BioNews 
The UK's Nuffield Council on Bioethics has published a report on the ethical and policy issues surrounding pharmacogenetics: the use of tests to match medicines to a person's genetic make-up. It concludes that although such tests may significantly improve the quality of patient care, it is still unclear how quickly...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.